DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (MALS verified)

Dengue is a mosquito-borne viral disease widely spread all over the world transmitted by 4 serotypes of dengue virus (DENV) . The symptoms range from mild dengue fever to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with high mortality. Currently, most of the studies on DENV vaccines emphasize on its envelope protein which is essential for viral attachment and fusion (i.e., Sanofi’s tetravalent dengue vaccine Dengvaxia) . However, the vaccine of envelope protein still needs to be improved to maximize its efficiency on people never infected with DENV before, which requires more research to be conducted on the DENV envelope protein.

This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 46.2 kDa. The protein migrates as 55-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (Cat. No. ENN-D5244) at 1 μg/mL (100 μL/well) can bind Human Anti-E(DENV) Antibody EDE2 A11,Human IgG1 | Human Kappa with a linear range of 1-39 ng/mL (QC tested).